Eravacycline: The Tetracyclines Strike Back

Area of Science:

• Pharmacology and Infectious Diseases
• Antibiotic Resistance
• Clinical Therapeutics

Background:

• The emergence of multidrug-resistant organisms (MDROs) necessitates new therapeutic options.
• Tetracycline-class antibiotics, including novel derivatives like eravacycline, are being investigated for their activity against resistant pathogens.

Purpose of the Study:

• To review the pharmacology, pharmacokinetics, efficacy, safety, and therapeutic role of eravacycline.
• To assess eravacycline's utility in treating infections caused by MDROs.

Main Methods:

• A comprehensive literature search was performed using PubMed and internet searches for clinical research.
• Included studies focused on eravacycline's clinical efficacy, safety, and pharmacokinetics in humans and animals.

Main Results:

• Eravacycline exhibits in vitro activity against a range of MDROs, including MRSA, VRE, ESBL-producing Enterobacteriaceae, and carbapenem-resistant Enterobacteriaceae.
• Phase III trials demonstrated eravacycline's efficacy in treating complicated intra-abdominal infections (cIAIs) compared to ertapenem and meropenem.
• Common adverse events included infusion site reactions, nausea, vomiting, and diarrhea.

Conclusions:

• Eravacycline is an effective new tetracycline antibiotic for treating cIAIs.
• Its broad spectrum of activity against MDROs makes it a valuable option, particularly when other antibiotics are contraindicated or ineffective.
• Further data are needed to establish its role in indications beyond cIAIs.